U034 Clinically Relevant Updates in Dermatopathology: Where Are the Gaps?
DESCRIPTION
Keeping up to date in dermatology subspecialties is challenging, yet it is beneficial to be aware of advances in dermatopathology, such as in immunohistochemistry and molecular techniques to assist in rendering a correct diagnosis. Additionally, new entities or variants of established entities are often introduced in dermatopathology journals, so shared knowledge of such could result in more accurate clinical-pathologic diagnoses. In this session, potential gaps in knowledge between clinical practice and dermatopathology advances are presented. These include a variety of topics such as melanocytic/non-melanocytic/lymphocytic neoplasms, drug-induced conditions, and systemic disease. Dermatologists and Dermatopathologists can benefit from this session.
LEARNING OBJECTIVES
Identify potential gaps in knowledge of clinically relevant developments in dermatopathology
Identify potential ways in which immunohistochemistry and molecular analysis can assist in diagnosis and management of melanocytic neoplasms.
Identify potential gaps in knowledge of primary cutaneous lymphomas
SCHEDULE
7:30 AM
Introduction
Jacqueline M. Junkins-Hopkins, MD, FAAD
7:32 AM
Melanocytic Neoplasms: Updates and Potential Gaps
Allen Gordon Strickler, MD, PhD, MPH, FAAD
7:47 AM
Q and A
Allen Gordon Strickler, MD, PhD, MPH, FAAD
7:50 AM
Selective Drug-induced Eruptions and Non-melanoma Skin Cancer: Updates and Potential Gaps
Emily Y. Chu, MD, PhD, FAAD
8:05 AM
Q and A
Emily Y. Chu, MD, PhD, FAAD
8:10 AM
Cutaneous Lymphoma and Miscellaneous Dermatopathology Topics: Updates and Potential Gaps
Jacqueline M. Junkins-Hopkins, MD, FAAD
8:25 AM
Q and A
Jacqueline M. Junkins-Hopkins, MD, FAAD
DIRECTOR
Jacqueline M. Junkins-Hopkins, MD, FAAD
SPEAKERS
Emily Y. Chu, MD, PhD, FAAD
Allen Gordon Strickler, MD, PhD, MPH, FAAD
DISCLOSURES
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Jacqueline M. Junkins-Hopkins, MD, FAAD
No financial relationships exist with ineligible companies.
Allen Gordon Strickler, MD, PhD, MPH, FAAD
No financial relationships exist with ineligible companies.